Imugene (ASX:IMU) said its Phase 1b clinical trial evaluating drug candidate azer-cel (azercabtagene zapreleucel) in patients with blood cancer achieved an overall response rate (ORR) of 81%, up from an ORR of 79% in August, according to a Thursday filing with the Australian bourse.
Thirteen out of sixteen patients showed a response to the treatment, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.